Cost-Effectiveness Analysis of the High-Dose Trivalent Influenza Vaccine in the Elderly Population in Italy
The findings suggest that the high-dose vaccine may improve health outcomes while reducing healthcare costs in people aged 65 and over in Italy.
High-Dose vs Standard-Dose Influenza Vaccines in Older Adults: A Meta-Analysis
Among adults 65 years and older, does high-dose inactivated influenza vaccine (HD-IIV) provide superior protection against hospitalization and mortality compared with the standard dose?
Influenza Vaccine and Associated Infection and Death in California, 2024 to 2025
Among adults aged 65 years and older with laboratory confirmed influenza, vaccination was associated with 29% lower likelihood of death due to influenza-related causes.
Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Updated analysis incorporating new evidence
HD-IIV remains cost-effective in Dutch adults aged ≥60.
Lessons from a global review of health system resilience
The review calls for coordinated action within and beyond the health system and across three interconnected areas.
Public consultation: Tobacco products and tobacco advertising – revision of EU rules
The EU intends to update its tobacco control rules in response to the latest market developments, consumption trends and digital marketing practices. Consultation closes 14 August 2026.
Call for tenders (HaDEA): Framework contracts to speed up the development of and access to next-generation therapeutics for infectious diseases
The scope of the call is expected to cover the development of innovative therapeutics to treat viral infections, acute respiratory distress syndrome (ARDS) or sepsis resulting from infections.
Commission signs joint procurement contract for up to 24 million doses of RSV vaccine ahead of the 2026-2027 winter season
The European Commission has signed a joint procurement framework contract with Moderna to access up to 24 million doses of the mRNA-based RSV (Respiratory Syncytial Virus) vaccine mRESVIA®.
